Pseudomonas aeruginosa is an opportunistic bacterium known for causing chronic infections in cystic fibrosis and chronic obstructive pulmonary disease (COPD) patients. Recently, several drug targets in Pseudomonas aeruginosa PAO1 have been reported using network biology approaches on the basis of essentiality and topology and further ranked on network measures viz. degree and centrality. Till date no drug/ligand molecule has been reported against this targets.In our work we have identified the ligand /drug molecules, through Orthologous gene mapping against Bacillus subtilis subsp. subtilis str. 168 and performed modelling and docking analysis. From the predicted drug targets in PA PAO1, we selected those drug targets which show statistically significant orthology with a model organism and whose orthologs are present in all the selected drug targets of PA PAO1.Modeling of their structure has been done using I-Tasser web server. Orthologous gene mapping has been performed using Cluster of Orthologs (COGs) and based on orthology; drugs available for Bacillus sp. have been docked with PA PAO1 protein drug targets using MoleGro virtual docker version 4.0.2.Orthologous gene for PA3168 gyrA is BS gyrAfound in Bacillus subtilis subsp. subtilis str. 168. The drugs cited for Bacillus sp. have been docked with PA genes and energy analyses have been made. Based on Orthologous gene mapping andin-silico studies, Nalidixic acid is reported as an effective drug against PA3168 gyrA for the treatment of CF and COPD.
Background:
Pseudomonas aeruginosa (PA) is a gram negative, rod-shaped and opportunistic bacterium known for causing chronic infections in cystic fibrosis and chronic obstructive pulmonary disease (COPD) patients [1] . Its mode of action involves adherence to tissue surface using its pili, flagellum and exo-S and replication to form a mass of cells. The bacterium gradually synthesizes biofilm for its prolonged attachment with host tissues and by its virulent factors causes severe tissue damage. The bio films protect these bacteria from adverse environmental factors, hence raised a serious problem for medical care in industrialised societies, especially for immune-compromised patients and the elderly [2] . PA is capable of acquiring resistance genes and hence, shows multiple drug resistance. The increasing number of multi drug resistant PA (MDRPA) strains has rendered many existing drugs as ineffective, including the most powerful anti-pseudomonal beta-lactams [1].
The capacity of PA to resist multiple front-line antibiotics makes the eradication of the organism nearly impossible [3] . This has rendered an urgent need of discovery of new drugs and drug/ligand molecules for treating infections caused by Pseudomonas aeruginosa. Recently, several drug targets for PA PAO1 are predicted using network biology [4] . A protein-protein interaction network shows all possible interactions between proteins of an organism. These interactions are weighed and are considered on the basis of datasets available for an organism. Hubs are identified using network measures viz. degree and centrality. Disruption of these hubs by drug/ligand molecules will cause disruption of essential pathways in the organism and will help in the treatment of infections. To address the issue of new drug/ligand discovery we have employed the Orthologous gene mapping approach to identify the suitable ligand molecule for the DNA Gyrase A target in PA POA1 and structure modelling subsequently, docking with various ligands [5] . Homologous sequences are orthologous if they were separated by a speciation event. Two organisms that are very closely related are likely to display very similar DNA sequences between orthologs [5] . Pseudomonas aeruginosa PAO1 is closely related to Bacillus subtilis and shows statistically significant orthologs with it. Hence, a drug against Bacillus subtilis could be effective against Pseudomonas aeruginosa as shown by our analysis.
DNA Gyrase is an enzyme that influences all metabolic processes involving DNA by regulating negative supercoiling of bacterial DNA and is essential for replication [6] . The enzyme gets inhibited by two classes of antimicrobials. This shows that its composition is from reversibly associated subunits [7] . Inhibition of GyraseA subunit affects breakage and rejoining of DNA, thereby, affecting metabolic pathways. Here, we have modelled the structures of predicted drug targets of PA PAO1 using I-Tasser. Following this, Orthologous gene mapping is done and a set of drugs that have been used for Bacillus subtilis, are docked with PA proteins. The energies obtained on docking with PA PAO1 proteins are comparable with Bacillus subtilis subsp. subtilis str. 168 as control. These drugs could be effective in overcoming PA multi drug resistant (MDRPA) problems as the drugs are directed against hubs found in the network.
Methodology:
In this study, primary focus is to identify the suitable drug molecules against DNA Gyrase A PA PAO1. Recently, several drug targets viz. PA0004gyrB, PA3168 gyrA, PA3482 metG, PA3834valS, PA3987 leuS, PA4238 rpoA, PA4268 rpsL, PA4269 rpoC, and PA4967 parE have been reported on the basis of network biology approch. We have selected PA0004 gyrB, PA3168 gyrA and PA3987 leuS, drug targets on the basis of finding statistically significant (orthologs; similar function in divergent species) in COG (cluster of orthologs) database. We collected orthogus genes in model organism Bacillus subtilis subsp. subtilis str. 168 and their corresponding known drug molecules. Drugs available for Bacillus sp. have been docked with proteins of PA PAO1and the ligands have been tested for drug-likeness, toxicity and other pharmacological properties. The results have been analyzed in terms of energies or 'poses' to give the best five poses which bind satisfactorily to the target protein. These molecules could be analysed in-vitro and in-vivo for confirmation and evaluation of its properties.
Retrieval of drug target and orthologous mapping
From reported drug targets in PA PAO1, we have selected PA0004, PA3168 and PA3987 for hypothesis of drug / ligand on the basis of statistically significant orthology in close model organisms. Orthologous genes have been found using Cluster 
Study of Ligand-Substrate Interactions
Interactions of different poses of ligands have been investigated on LigandScout 3.0.3 software package. Pharmacophores are an ensemble of universal chemical features that characterises a specific mode of action of a ligand in the active site of the macromolecule in 3-D space necessary to ensure the optimal interactions with a specific biological target and to trigger (or block) its biological response. In other words it is the 3D arrangement of functional groups that enable a compound to exert particular biological effects. Pharmacophores corresponding to all the drugs have been studied and comparative differences of interactions between drug-drug targets have been identified. The optimal interactions between drug-drug targets and Chemical features including hydrogen bonding, charge interactions and hydrophobic areas are depicted in Figure 1(C) & Figure 1(D) . 
Conclusion:
Orthologous gene mapping of Pseudomonas aeruginosa PAO1genes namely PA0004, PA3168 andPA3987 showed orthology with BSgyrB, BSgyrA and BSleuS genes of Bacillus subtilis subsp.subtilis str. 168 respectively. Drugs have been found for PA3168 (DNA Gyrase subunit A), PA0004 (DNA Gyrase subunit B), and PA3987 (leucyl tRNA synthetase) based on orthologous genes found in Bacillus subtilis subsp. subtilis str.168. Nalidixic Acid is reported as an excellent inhibitor for Gyrase A in Bacillus sp. and have been found to show comparable energies and hydrogen bonding levels in PA PAO1 orthologous gene (statistically significant) PA3168 while the docking results of target PA3168 drug target of PA PAO1 with other drug molecules namely 2-hydroxyquinoline, Oxolinic Acid, Norfloxacin and Ciprofloxacin cited for BS gyr A of Bacillus subtilis subsp. subtilis str.168 were not comparable. Thus, our study suggests that Nalidixic acid drug molecule could be a potential DNA Gyrase A inhibitor in PA PAO1, which could be validated by in-vitro experiments. Further, the computer aided drug discovery process along with genomic information of drug targets may enhance our understanding towards in-sight of mechanism of drug-target interactions and their binding patterns. 
